TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6793298
Drug: NET or
Normalized name: lactase / rennet Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NET or EDA preparations
Study: 6793298
Drug: LNG preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG preparation
Study: 20336327
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) during intravenous chemotherapy
Study: 20336327
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no VR during intravenous chemotherapy)
Study: 18292082
Drug: 4% amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% amethocaine gel (AnGEL)
Study: 16542370
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 14 days
Study: 10634372
Drug: Orbital radiotherapy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiotherapy (telecobalt) in 20 fractions of 1 Gray (Gy) weekly over 20 weeks (group A)
Study: 10634372
Drug: Orbital radiotherapy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiotherapy (telecobalt) in 10 fractions of 1 Gy daily over 2 weeks (group B)
Study: 10634372
Drug: Orbital radiotherapy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiotherapy (telecobalt) in 10 fractions of 2 Gy daily over 2 weeks (group C)
Study: 7960186
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment preceding gamete recovery
Study: 7960186
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of peroxidase-positive cells (> 6 x 10(6)/ml)
Study: 3296741
Drug: Metolazone-furosemide combination
Normalized name: Metolazone
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metolazone-furosemide combination
Study: 3296741
Drug: Thiazide-furosemide combination
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiazide-furosemide combination
Study: 29089415
Drug: Periprocedural heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprocedural heparin (HEP+)
Study: 20056180
Drug: S. sonnei
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. sonnei conjugate (25 microg, injected IM twice, 6 weeks apart)
Study: 20056180
Drug: S. flexneri
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. flexneri 2a conjugate (25 microg, injected IM twice, 6 weeks apart)
Study: 12196364
Drug: CTC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC chemotherapy (high-dose cyclophosphamide, thiotepa, carboplatin)
Study: 12196364
Drug: FEC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC chemotherapy (standard-dose fluorouracil, epirubicin, cyclophosphamide)
Study: 12196364
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (conventional cyclophosphamide, methotrexate, 5-fluorouracil)
Study: 7650223
Drug: Draflazine 2
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Draflazine 2 mg
Study: 7650223
Drug: Draflazine 4
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Draflazine 4 mg
Study: 7650223
Drug: Draflazine 6
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Draflazine 6 mg
Study: 795440
Drug: D-oxazepam hemisuccinate
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-oxazepam hemisuccinate sodium salt (100 mg i.m.)
Study: 795440
Drug: Racemic form
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic form of D-oxazepam (100 mg i.m.)
Study: 7012246
Drug: Intraventricular amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraventricular amikacin (5 mg via Rickham reservoir)
Study: 7012246
Drug: Intraventricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular therapy
Study: 28831839
Drug: Customized sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized sound therapy
Study: 28831839
Drug: Broadband noise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broadband noise therapy
Study: 19893125
Drug: Intranasal electrophoresis
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal electrophoresis of vanadium
Study: 15096905
Drug: Amlodipine 2.5
Normalized name: amlodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5 mg per day
Study: 11966786
Drug: Mucopolysaccharide-cartilage complex
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopolysaccharide-cartilage complex (MCC) healing ointment
Study: 18310201
Drug: Aquaphor ointment
Normalized name: Aquaphor Ointment Topical Body Spray
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquaphor ointment
Study: 7666251
Drug: Wheat bread-based
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bread-based diet (daily intake 274 g starch, 2.4 g enzyme-resistant starch, 14.4 g total dietary fiber)
Study: 7666251
Drug: Oat bran-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran-based diet (daily intake 243 g starch, 2.7 g enzyme-resistant starch, 40.2 g total dietary fiber)
Study: 2711724
Drug: Intracervical Prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Prostaglandin E2 (PGE2) gel application within 6 hours after PROM
Study: 2711724
Drug: Intracervical Prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Prostaglandin E2 (PGE2) gel application within 7-12 hours after PROM
Study: 2711724
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion after 12 hours of waiting
Study: 798636
Drug: Formalin‐inactivated cholera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated cholera vaccine
Study: 798636
Drug: Partially purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially purified toxoid preparation
Study: 798636
Drug: Whole‐cell heat‐killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐cell heat‐killed cholera vaccine
Study: 798636
Drug: Whole‐cell heat‐killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐cell heat‐killed El Tor vaccine
Study: 29078762
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment program for high fracture risk women in the intervention group, based on screening program including FRAX, DXA, and IVA.
Study: 26630467
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg daily for 14 days postoperatively
Study: 26630467
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Aspirin and Control)
Study: 17325089
Drug: Intravenous ampicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ampicillin/sulbactam for 48 hours followed by oral amoxicillin/clavulanate for 7 days
Study: 17325089
Drug: Clindamycin for
Normalized name: Clindamycin for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin for 48 hours followed by oral clindamycin for 7 days
Study: 15361375
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (non-adherent group)
Study: 15361375
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methotrexate (non-adherent group)
Study: 12047964
Drug: de Gramont
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: de Gramont regimen (folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days 1 and 2, repeated every 14 days)
Study: 12047964
Drug: Lokich regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lokich regimen (protracted venous infusion of fluorouracil 300 mg/m(2) daily)
Study: 12047964
Drug: raltitrexed (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: raltitrexed (3 mg/m(2) intravenously every 21 days)
Study: 9474447
Drug: High-dose ECT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ECT (2.5 x threshold)
Study: 7699188
Drug: High-fat, high-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat, high-energy nutrition supplement consumed at a maximum of 30% of estimated daily energy requirements
Study: 7699188
Drug: High-fat, high-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat, high-energy nutrition supplement
Study: 29058112
Drug: Glutamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 0.25 g kg‐1 FFM
Study: 29058112
Drug: Glutamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 0.5 g kg‐1 FFM
Study: 29058112
Drug: Glutamine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 0.9 g kg‐1 FFM
Study: 17349882
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of atorvastatin
Study: 17349882
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of ezetimibe plus 10 mg/day of atorvastatin
Study: 15292365
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (250 microg/hr)
Study: 3622197
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) group, 0.71 ± 0.12 g X kg‐1 X day‐1 protein for 4.5 ± 1 months
Study: 3622197
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (NPD) group, 1.44 ± 0.12 g X kg‐1 X day‐1 protein for 11.7 ± 7 months
Study: 24243080
Drug: EMLA(®) 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA(®) 5% cream
Study: 16204662
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery catheter (PAC) guided therapy
Study: 10396888
Drug: Interdisciplinary psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary psychoeducational family group intervention (7 weekly, 2-hour sessions)
Study: 1539456
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis DTP vaccine containing 12.5 micrograms (AC-12.5)
Study: 1539456
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis DTP vaccine containing 25 micrograms (AC-25)
Study: 1539456
Drug: Acellular vaccines
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccines (AC-12.5 and AC-25)
Study: 1539456
Drug: Acellular vaccine
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccine (AC-12.5)
Study: 3104512
Drug: Prophylactic i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic i.v. nitroglycerin at a dose of 0.7 microgram/kg‐1/min‐1
Study: 31557492
Drug: PF-5190457 (GHS-R1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-5190457 (GHS-R1a inverse agonist)
Study: 27132086
Drug: Standard abortive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard abortive or preventive antimigraine treatment (n=7)
Study: 10884878
Drug: Trimethoprim‐sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (160 mg trimethoprim, 800 mg sulfamethoxazole)
Study: 2185962
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg, orally, twice daily for 4 weeks)
Study: 2185962
Drug: Placebo (orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally, twice daily for 4 weeks)
Study: 6996660
Drug: Oral practolol
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral practolol 200 mg twice daily
Study: 12211224
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg bid)
Study: 23439357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ulinastatin and tranexamic acid
Study: 12601217
Drug: 1.0 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mol/L gadobutrol
Study: 12601217
Drug: 0.5 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mol/L gadobutrol
Study: 10672435
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of controlled‐release melatonin
Study: 7952047
Drug: L-alpha-glycerophosphorylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alpha-glycerophosphorylcholine (1 g)
Study: 2959917
Drug: Etretin 40
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretin 40 mg
Study: 2959917
Drug: Etretinate 40
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate 40 mg
Study: 31695168
Drug: Escitalopram, Sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, Sertraline, Venlafaxine-XR (antidepressants)
Study: 30091952
Drug: Golimumab in
Normalized name: golimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab in combination with methotrexate
Study: 31908843
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with methotrexate
Study: 28647668
Drug: Early improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early improvement (Hamilton Depression Rating Scale reduction > 20% after 14 days of treatment)
Study: 25808818
Drug: Favipiravir (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir (acute administration for 1 day)
Study: 25808818
Drug: Favipiravir (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir (extended administration for 6 days)
Study: 25808818
Drug: Favipiravir co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir co-administration
Study: 20501622
Drug: Rapamycin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin 3 mg
Study: 18707820
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin (area under the curve of 2) during RT
Study: 16517502
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of DHA and 150 mg of EPA
Study: 12650950
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg)
Study: 8800165
Drug: Early extubation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early extubation group (n = 60; 15 micrograms.kg‐1 fentanyl and 2 to 6 mg.kg‐1.hour‐1 propofol and isoflurane)
Study: 8800165
Drug: Conventional extubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional extubation group (n = 60; 50 micrograms.kg‐1 fentanyl and 0.1 mg.kg‐1 midazolam and isoflurane)
Study: 1386224
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg with Sufentanil 25 micrograms
Study: 26868507
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day)
Study: 23632408
Drug: 3.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% lidocaine gel applied without pressure
Study: 22094937
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m²) + Paclitaxel (175 mg/m²)
Study: 22094937
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m²) + Paclitaxel (155 mg/m²) + Capecitabine (825 mg/m² BID for 14 days)
Study: 19016569
Drug: 20-mL syringe
Normalized name: thiopental
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-mL syringe with vacuum obtained by a hand-grip device (Group 1)
Study: 19016569
Drug: 4-mL Vacutainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mL Vacutainer connected to the needle (Group 2)
Study: 12452872
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation (cumulative doses of 96 J cm‐2 for skin type II and 126 J cm‐2 for skin type III)
Study: 8129608
Drug: Preoperative, noninvasive:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative, noninvasive: The redox tolerance test (RTT) measuring changes in arterial ketone body ratio in response to 75 g of oral glucose loading.
Study: 9032569
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol alone
Study: 31645305
Drug: Blood components
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood components therapy
Study: 29019364
Drug: Blueberry treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry treatment (BB; 300 g of blueberry)
Study: 29019364
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (C; 300 mL of water with sugar)
Study: 29019364
Drug: Blueberry treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry treatment with smoking (BS; 300 g of blueberry + smoking)
Study: 29019364
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with smoking (CS; 300 mL of water with sugar + smoking)
Study: 29019364
Drug: Smoking treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking treatment (S)
Study: 19826306
Drug: Carbohydrate-electrolyte beverage
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte beverage (6% or 60 g L(‐1))
Study: 17082474
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF) 10 microg/kg for 5 days
Study: 11297210
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (10(6) KIU after induction of anesthesia and 10(6) KIU in pump prime)
Study: 9226484
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of water soluble fibre (guar gum) daily for 14 months
Study: 2888185
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg HOE 760
Study: 28084834
Drug: Interactive Behavioral
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Behavioral Modification Therapy
Study: 27480314
Drug: Protocolized sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized sedation with daily sedation interruption
Study: 25527842
Drug: Corticosteroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid and local anaesthetic injections administered by a physiotherapist
Study: 25527842
Drug: Corticosteroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid and local anaesthetic injections administered by an orthopaedic surgeon
Study: 22898679
Drug: Imatinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib with chemotherapy (good-risk group)
Study: 22898679
Drug: No imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: No imatinib with chemotherapy (good-risk group)
Study: 22898679
Drug: Imatinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib with chemotherapy (as-treated analysis, good-risk group)
Study: 22898679
Drug: No imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: No imatinib with chemotherapy (as-treated analysis, good-risk group)
Study: 22898679
Drug: Imatinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib with chemotherapy (poor-risk group)
Study: 20384990
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to clinical practice guidelines (CPGs)
Study: 20384990
Drug: Non-treatment or
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment or treatment not according to CPGs
Study: 18362489
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 4 weeks
Study: 12163992
Drug: Concomitant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly for 6 courses and HDR brachytherapy (7 Gy in point A per fraction, total dose 35 Gy)
Study: 7486115
Drug: Propofol blood
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol blood concentration 1 microgram/mL
Study: 7486115
Drug: Propofol blood
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol blood concentration 2 micrograms/mL
Study: 6769773
Drug: Oral thioctic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thioctic acid for 21 days
Study: 6769773
Drug: Intravenous thioctic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thioctic acid for 21 days
Study: 25403264
Drug: Pomalidomide plus
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide plus low-dose dexamethasone (POM+LoDEX)
Study: 26149712
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HiDEX)